Showing results (51-60 of 472) with videos related to
Sort By:
Pageof 48
Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.Cardiovascular Research|August 12, 2003
Influence of differential vascular remodeling on the coronary vasomotor responseAndrew L McLeod, David E Newby, David B Northridge, et al.International Journal of Cardiology|December 13, 2018
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI populationFrançois Schiele, Etienne Puymirat, Jean Ferrières, et al.Particle and Fibre Toxicology|June 8, 2013
Exposure to wood smoke increases arterial stiffness and decreases heart rate variability in humansJon Unosson, Anders Blomberg, Thomas Sandström, et al.Nanomedicine (London, England)|March 13, 2013
Nanoparticles and the cardiovascular system: a critical reviewKen Donaldson, Rodger Duffin, Jeremy P Langrish, et al.Journal of the American College of Cardiology|May 11, 2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS TrialKeith A A Fox, John W Eikelboom, Olga Shestakovska, et al.Circulation|February 4, 2010
Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromesClara K Chow, Sanjit Jolly, Purnima Rao-Melacini, et al.Circulation|August 16, 2006
Adverse impact of bleeding on prognosis in patients with acute coronary syndromesJohn W Eikelboom, Shamir R Mehta, Sonia S Anand, et al.Journal of the American College of Cardiology|January 18, 2005
Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3)Joseph Kim, Robert A Henderson, Stuart J Pocock, et al.Hypertension (Dallas, Tex. : 1979)|October 20, 2004
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibitionNicholas L M Cruden, Keith A A Fox, Christopher A Ludlam, et al.Pageof 48